DadFinStart your free week
DadFin › Stocks › Healthcare › LNTH

Lantheus Holdings, Inc. (LNTH) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · United States

$100.15 ▲ +0.03% today

81.9
Dad Score, out of 100
good

Lantheus Holdings, Inc. (LNTH) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 81.9 out of 100 on the Dad Score, a good reading that places the business ahead of 82% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #161 of 974. Its strongest axes are valuation, quality and conviction; its weakest are growth and risk.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Above average
Growth
Below average
Price action
Average
Risk
Below average
Conviction
Strong
Liquidity
Strong
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)23.9×
P/E (forward)15.7×
Dividend yield0.00%
Return on capital17.6%
Operating margin25.8%
Revenue growth (YoY)+0.5%
FCF yield5.2%
Net debt / EBITDA0.08×
Piotroski F-Score5 / 9
52-week change+89.7%
Market cap$6.5B
Next earningsNov 5, 2026

What subscribers see on LNTH

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TAKTakeda Pharmaceutical Company Limi32.9weak$57.1B
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.